Interim analysis of a phase 3 trial in 488 patients with relapsed or refractory follicular lymphoma: adding epcoritamab to R2 raised response (95% vs 79%) and prolonged PFS (HR 0.21), but grade ≥3 adverse events were more frequent (90% vs 68%).
RCTn = 488
Falchi et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial